Meeting
2020 ASCO Virtual Scientific Program
TRIDENT-1: A global, multicenter, open-label Phase II study investigating the activity of repotrectinib in advanced solid tumors harboring ROS1 or NTRK1-3 rearrangements.
Presenter
Robert Charles Doebele, MD, PhD
University of Colorado
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03093116
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS9637)
DOI
10.1200/JCO.2020.38.15_suppl.TPS9637
Abstract #
TPS9637
Poster Bd #
403
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2023 ASCO Annual Meeting
Intracranial and systemic efficacy of repotrectinib in advanced ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) and central nervous system metastases (CNS mets) in the phase 1/2 TRIDENT-1.
Speaker: Jessica Jiyeong Lin, MD
Videos & Slides
2020 ASCO Virtual Scientific Program
An open-label, multicenter, phase II study of ceritinib in patients with advanced ALK+ non-lung solid tumors and hematological malignancies (ASCEND-10).
Speaker: Victor Moreno, MD, PhD
Speaker: Lori J. Pierce, MD
Videos & Slides
2024 ASCO Annual Meeting
Nivolumab combined with radical chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): An investigator-initiated, open-label, multicenter, single-arm, phase II clinical trial.
Speaker: Cheng Xu, MD